With economic crosswinds buffeting regional markets, income-focused investors are increasingly looking to dividend-paying equities in Asia to anchor their portfolios. We examine three prominent names offering compelling yields.
Vaxcyte's shares have surged over 38% in three months, reigniting debate on whether the clinical-stage biotech is undervalued or if investors are overlooking significant risks in its unproven pipeline.
While global small- and mid-cap stocks face headwinds, savvy investors are turning to Asia for overlooked opportunities. We examine three fundamentally strong companies with compelling growth trajectories.
A notable easing of US-Iran tensions has buoyed investor confidence across Gulf bourses, creating a favorable backdrop for stable, income-generating equities. We analyze three regional dividend stocks offering potential portfolio resilience amid shifting market dynamics.
As Equitable Holdings prepares to report fourth-quarter results, investors are watching for signs of stability amid a turbulent period for insurance stocks. With revenue growth expected to stall, the focus shifts to profitability and guidance.
Industrial manufacturer IDEX (IEX) is set to release its quarterly results Wednesday morning, with Wall Street anticipating a slight revenue increase. The report comes amid a broader rally in fluid and gas handling stocks.
French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.
Once a high-flying AI discovery platform, AbCellera Biologics is navigating a critical transition to a clinical-stage biotech. With a fortified balance sheet and key Phase 1 readouts on the horizon, some investors see a compelling, albeit risky, turnaround story taking shape.
Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.
Amidst a complex macroeconomic backdrop, a select group of Asian small-cap stocks is capturing attention for their distinct value propositions and growth narratives. We examine China Feihe, Digital China Holdings, and Thai Beverage, assessing their financial health and strategic positioning in volatile markets.
As large-cap stocks dominate headlines, a search for value turns to Asia's smaller players. We examine three companies—from logistics to tech to construction—that combine strong fundamentals with compelling valuations, offering potential for investors looking beyond the index giants.
Cocoa prices edged higher Monday, finding a brief respite from a prolonged slump as delivery slowdowns in top grower Ivory Coast triggered short-covering. However, the rally remains fragile, overshadowed by bulging global stocks, weak demand, and forecasts for a continued supply surplus.
Cocoa futures gained ground on Monday, reversing recent losses, as data showing reduced deliveries to ports in top-producer Ivory Coast triggered short-covering. The uptick comes despite a backdrop of ample global stocks and persistent demand weakness in key markets.
U.S. stocks advanced cautiously Monday as investors braced for a wave of corporate earnings reports, while crude oil prices tumbled sharply. The focus remains on key tech results and evolving geopolitical developments affecting global trade and energy markets.
U.S. stocks advanced Monday, buoyed by a surprisingly strong manufacturing report that overshadowed lingering concerns over a partial government shutdown and weak economic data from China. The S&P 500 and Dow Jones Industrial Average both closed higher, led by a rebound in semiconductor and AI-related shares.
U.S. equities edged higher Monday, buoyed by a rebound in semiconductor and AI infrastructure stocks, alongside a surge in rare earth companies following a new strategic initiative. Gains were tempered by falling energy shares, cryptocurrency volatility, and ongoing concerns over a partial government shutdown.
A powerful but uncommon shift in market leadership is underway as small-caps, energy, and value stocks drive gains. While a sign of health, historical parallels to similar 'breadth' events often coincided with economic stress.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Despite promising mid-stage clinical data and billion-dollar sales potential for its mRNA pipeline, Arcturus Therapeutics (ARCT) is trading near its cash value—a signal the market is assigning near-zero odds to its success. This stark disconnect has analysts debating whether the biotech firm is a glaring mispricing or a high-risk bet.
